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The opposite effects of insulin and glucagon in fuel homeostasis, the paracrine/endocrine inhibitory effects of
insulin on glucagon secretion and the hyperglucagonemia in the pathogenesis of type 2 diabetes (T2D) have
long been recognized. Inappropriately increased alpha-cell function importantly contributes to hyperglycemia and
reflects the loss of tonic restraint normally exerted by high local concentrations of insulin on alpha-cells, possibly as
a result of beta-cell failure and alpha-cell insulin resistance, but additional mechanisms, such as the participation of
incretin hormones in this response, have also been suggested. Three classes of drugs already available for clinical
use address the abnormalities of glucagon secretion in T2D, namely, the GLP-1 receptor agonists (GLP-1RA), the
inhibitors of dipeptidyl peptidase-4 (DPP-4i) and the amylin agonist pramlintide; it has been proposed that the
glucagonostatic and insulinotropic effects of GLP-1RA equally contribute to their hypoglycemic efficacy. In this
review, the control of glucagon secretion and its participation in T2D pathogenesis are summarized.
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The existence of glucagon was suggested by Murlin
et al. [1] in 1923, right after insulin discovery, to explain
the precocious hyperglycemic effect of pancreatic extracts,
which, according to their hypothesis, was contaminated
with a GLUCose AGONist substance. In 1948, Sutherland
and de Duve [2] defined the alpha-cells of the islets of
Langerhans as the source of glucagon as well as the ac-
tions of this hormone stimulating hepatic glycogenolysis
and gluconeogenesis in hypoglycemic conditions. In 1959,
Unger et al. [3] reported a glucagon radioimmunoassay.
Insulin and glucagon participate in fuel homeostasis,
being reciprocally released in response to glycemic oscilla-
tions; insulin prevails in the fed state, promoting glucose
uptake by its target organs whereas glucagon mobilizes
hepatic glucose in the fasting state to ensure the mainten-
ance of normoglycemia [4]. The protective mechanisms
against hypoglycemia include suppression of insulin secre-
tion and rise of counterregulatory hormones, especially
glucagon and epinephrine.Correspondence: godoymatos@openlink.com.br
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ectly stimulates glucagon release during hypoglycemia,
the paracrine/endocrine (interstitium/microcirculation)
inhibitory effects of insulin and somastostatin on gluca-
gon secretion are relatively well established [5]. The
alpha-cells abundantly express insulin receptors and insu-
lin activates ATP-sensitive K+-channels with consequent
membrane hyperpolarization [6]. Another mechanism in-
volved in alpha-cell membrane hyperpolarization and glu-
cagon suppression by insulin in rodent islets is the
activation of gamma-aminobutyric acid (GABA) receptors
through an AKT kinase-dependent pathway [7]. Somato-
statin released by delta-cells also activates K+-channels in
the alpha-cells, besides inhibiting adenylate cyclase activ-
ity, cAMP content and protein kinase A (PKA)-stimulated
glucagon secretion [5]. Finally, insulin inhibits progluca-
gon gene transcription, possibly representing a long-term
mechanism for regulating alpha-cell function [8]. Beyond
this paracrine regulation, glucagon secretion is influenced
by autonomic factors originating in brain, where the
ventromedial hypothalamus (VMH) is recognized as an
important hypoglycemia-sensing area that can modulate
glucagon release [9].
Glucagon secretion is also stimulated by the incretin
hormone glucose-dependent insulinotropic peptide (GIP)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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that, unlike rat islets, human islets undergo a weak stimu-
latory effect of adrenaline on glucagon secretion), and is
suppressed by leptin [10], amylin [11] and glucagon-like
peptide-1 (GLP-1). GLP-1 is an insulinotropic incretin
hormone derived from the same gene that encodes glu-
cagon, proglucagon, which originates a preproprotein
cleaved into distinct mature peptides depending on the
enzyme involved in its post-translactional process; pro-
convertase (PC)2 in alpha-cells gives rise to glucagon
and PC1/3 in intestinal L-cells generates GLP-1 [12].
Interestingly, GLP-1 and PC1/3 immunoreactivity has
been detected in subsets of alpha-cells [13,14], suggest-
ing that glucagon secretion may also be directly regu-
lated by pancreatic GLP-1 [13].
The mechanism by which GLP- 1 decreases glucagon
secretion is a matter of debate; reports regarding the ex-
pression of GLP-1 receptors in alpha-cells have ranged
from absent [15], to very low [16] and to present in 20%
of the alpha-cells [17]. Recently, De Marinis et al. re-
ported the expression of GLP-1 receptors in alpha-cells
is <0.2% of that in beta-cells and that GLP-1-induced
suppression of glucagon release is dependent of PKA
and independent of glucose or paracrine effects medi-
ated by insulin or somatostatin [18]. On the other hand,
de Heer et al. [19] have previously demonstrated that
GLP-1 inhibitory effect on glucagon secretion is medi-
ated by somatostatin acting on somatostatin receptor
subtype-2 (SSTR-2).
Type 2 diabetes and impaired incretin effect
Type 2 diabetes mellitus (T2D) is characterized by insu-
lin resistance secondary to abnormalities triggered byFigure 1 Main contributors to hyperglycemia in Type 2 diabetes mellnutrional overload associated with deficient insulin se-
cretion. The latter condition results from a partial loss
of beta-cell mass and beta-cell dysfunction, both influ-
enced by genetic factors and by the chronic exposure of
pancreatic islets to glucolipotoxicity, to amylin, the
main component of amyloid fibril deposits [20] and to
advanced-glycated endproducts [21] (Figure 1).
In 1986, Nauck et al. described a reduced incretin ef-
fect in T2D patients, which explains the fact that the
insulinotropic incretin hormones GIP and GLP-1 ac-
count for <20% of postprandial insulin response [22],
while in non-diabetic individuals, both incretin hor-
mones are responsible for 50-70% of the postprandial in-
sulin response [23]. Since then, several studies have
addressed the potential mechanisms underlying the re-
duction in incretin effect in T2D and, to make a long
history short, the hypotheses raised by Juris Meier and
Michael Nauck are summarized hereafter.
These authors propose that reductions in GIP and
GLP-1 secretions do not appear to contribute signifi-
cantly to the loss of incretin effect and that there is a re-
duction in the insulinotropic action of GIP (whereas
GLP-1 action is relatively well preserved) secondarily to
a general impairment in beta-cell function. Additionally,
hyperglycemia further decreases beta-cell response to
GIP because it downregulates its receptor in this cell
type (Figure 1).
According to their assumption, the reduction of the
incretin effect in T2D patients is an epi-phenomenon of
chronic hyperglycemia, irrespective of primary defects in
GIP or GLP-1 action [24], which is consistent with the
finding of loss of GIP insulinotropic efficacy in patients
with diabetes of other etiologies, such as secondary toitus. AGE: advanced glycation endproducts.
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1 alpha mutations, and autoimmune diabetes with pre-
served beta-cell function [25]. Another finding that
corroborates the reduction of incretin effect in T2D as a
by-product of prolonged hyperglycemia is the improve-
ment of insulin secretion in response to oral compared
with intravenous glucose in patients submitted to inten-
sified insulin treatment who significantly improved gly-
cemic control [26].
Even though the reduced incretin effect may be a con-
sequence rather than a causal factor of T2D, some stud-
ies have shown that it might be an early sign of impaired
glucose metabolism detected before other signs of beta-
cell dysfunction are apparent [27]. This is exemplified by
the study of Hansen et al., who induced insulin resist-
ance and reduced glucose tolerance in healthy young
males (without a family history of diabetes) after daily
oral administration of 37.5 mg of prednisolone plus a
high-calorie diet and physical inactivity during 12 days
and observed a decrease in the incretin effect from 72 ±
5 to 43 ± 7%, while the insulin response to intravenous
glucose was capable of completely compensate the im-
paired insulin sensitivity [28].
Hyperglucagonemia in T2D development
Although the pathogenesis of T2D is classically focused
on insulin resistance and beta-cell dysfunction, the in-
appropriately increased alpha-cell function and conse-
quent hyperglucagonemia has long been recognised as a
contributor to hyperglycemia in diabetic patients, by
stimulating hepatic glucose production [29] (Figure 1).
Indeed, elevated fasting concentrations of glucagon, as
well as impaired glucose-induced glucagon suppression
and a disrupted insulin–glucagon interaction in the post-
prandial period, were described in T2D patients, differ-
ently from healthy subjects who present plasmatic
glucagon and insulin concentrations inversely related in
the postprandial state. The loss of the inverse relation-
ship between these two hormones in T2D patients might
be secondary to the observed diminished mass of insulin
pulses, and suggests that alterations in the cross-talk be-
tween beta- and alpha-cells may underlie hyperglucago-
nemia [30].
In 1984, Borghi et al. reported that obese non-diabetic
insulin-resistant and obese glucose-intolerant subjects
already exhibited impaired oral glucose-induced glucagon
suppression, even in presence of endogenous hyperinsuli-
nemia and hypothesized that alpha-cells might be resistant
to the insulin’s suppressive effect on glucagon secretion
[31]. In 2007, Ferrannini et al. [32] measured insulin re-
sistance by the euglycaemic–hyperinsulinaemic clamp in
1,296 non-diabetic individuals and demonstrated that
whole-body insulin resistance is independently associated
with elevated fasting glucagon concentrations, possibly asa result of alpha-cell insulin resistance. The confirmation
of the direct in vivo role of insulin signaling in the modu-
lation of alpha-cell function was provided by the condi-
tional alpha-cell specific insulin receptor knock-out
(αIRKO) mice, which exhibited up to 50% higher glucose
levels compared to control animals in the fed state, as well
as hyperglucagonemia [33].
Unger and Orci [34] have recently introduced the term
paracrinopathy to designate the loss of tonic restraint
normally exerted by a high local concentration of insulin
on alpha-cells; beta-cell destruction and beta-cell failure
to secrete the first phase of insulin associated with
alpha-cells insulin resistance would be the main mech-
anistic factors in type 1 and type 2 diabetes, respectively.
Besides the lack of inhibitory tone exerted by insulin
on glucagon release, other mechanisms have been inves-
tigated to explain the inappropriate increased alpha-cell
function in T2D. Motivated by the findings of some
studies showing that T2D patients, in contrast to their
improper glucagon response to oral glucose, are able to
suppress glucagon release after an isoglycemic intraven-
ous glucose infusion (IIGI) similarly to non-diabetic sub-
jects, Lund et al. evaluated the role of GIP, GLP-1 and
glucagon-like peptide-2 (GLP-2) in this discrepant re-
sponse. Therefore, plasmatic glucagon concentrations
were measured during a 3-h, 50-g oral glucose overload
or an IIGI in ten T2D patients; four additional IIGI were
performed in which GIP, GLP-1, GLP-2 or a combin-
ation of the three were intravenously infused. While no
suppression of glucagon was observed during the initial
phase of the oral glucose overload, significantly lower
plasmatic concentrations of this hormone were ob-
served during the first 30 min of the IIGI. The glucagon re-
sponse during the IIGI performed with infusion of GIP +
GLP-1 +GLP-2 was inappropriate and mimicked the one
observed after the oral glucose overload; infusion of GIP
alone promoted significant hypersecretion of glucagon,
whereas infusion of GLP-1 alone enhanced glucagon
suppression during the IIGI. These authors suggested
that the improper hyperglucagonemic response to
oral glucose could be dependent on the release of the
intestinal hormones, especially GIP, which seems to
play an important role in this pathophysiological fea-
ture [35].
In the pathophysiology of T2D a disbalance in beta-to-
alpha-cell ratio, mainly due to beta-cell apoptosis, has
also been suggested as a mechanism contributing to a
decreased insulin-to-glucagon ratio. However, a new
possible mechanism has been put forward in an animal
model, suggesting that, under stress demand, beta-cell
dedifferentiation to progenitor pluripotent cells takes
place. These cells may begin to express, and eventually
release, glucagon and somatostatin [36], further contrib-
uting to decreased insulin-to-glucagon ratio.
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Unger and Cherrington [37] have proposed a “glucago-
nocentric” vision of diabetes pathophysiology, and their
arguments for defending this point of view include the
following facts: glucagon augments the catabolic pro-
cesses occurring in the absence of insulin; hypergluc-
agonemia is present in all forms of poorly controlled
diabetes and leptin and somatostatin, known glucagon
suppressors, abrogate the catabolic manifestations of
diabetes during total insulin deficiency. Perhaps the
most astonishing fact had been the finding that glucagon
receptor–null mice do not develop diabetes following
complete beta-cell destruction [38]. More recently, Omar
et al. suggested that the explanation for the absence of
hyperglycemia in this mice model may not only be the
lack of glucagon effects, but also the presence of high con-
centrations of fibroblast growth factor 21 (FGF-21) and
GLP-1 exhibited by these mice. They demonstrated that
the concurrently neutralization of FGF-21 (with a FGF-21
antibody) and GLP-1 (with its antagonist Exendin 9–39)
actions resulted in hyperglycemia in those insulin deficient
glucagon receptor null mice [39].
Three classes of drugs already available for clinical use
address the abnormalities of glucagon secretion in T2D,
namely, the GLP-1 receptor agonists (GLP-1RA), the in-
hibitors of dipeptidyl peptidase-4 (DPP-4i), enzyme that
degrades GLP-1 (and other peptides and cytokines) and
the amylin agonist pramlintide. The first two classes also
exert insulinotropic effects, and the reason why they do
not markedly increase plasmatic concentrations of insulin
and C-peptide is thought to be in part due to the effect of
GLP-1 signaling to lower glycemia, decreasing the stimu-
lus to the beta-cells [40]. Hare et al. [41] suggested that
the effect of GLP-1 consists of the improvement of
glucose-induced insulin secretion, resulting in rather un-
changed absolute secretion rates, while glucagon secre-
tion, which would have been expected to augment with
falling glucose concentrations, actually reduces. These
authors propose that the glucagonostatic and insulinotro-
pic effects of GLP-1 equally contribute to its hypoglycemic
efficacy. In clinical settings, treatment of T2D patients
with a DPP-4i, vildagliptin, reduced post-meal glucagon
concentrations after 4 weeks of treatment in a manner
that the 2-h glucose decrement was significantly related to
the 1-h glucagon reduction [42]. In the same way, the
GLP-1RA liraglutide significantly reduced the 24-h area
under the curve (AUC) of glucagon in comparison to pla-
cebo (AUC= 2,179 ± 118 vs 2,371 ± 135, respectively; P =
0.037), primarily as a result of a marked reduction in
glucagon concentrations after the evening meal [43].
Interestingly, in C-peptide negative Type 1 diabetes pa-
tients, liraglutide decreased glucagon after a mixed meal
and improved glycemic control while reducing insulin
needs [44]. These findings suggest that liraglutide mayact inhibiting glucagon regardless of intra-islet insulin,
through GLP-1 receptor in alpha-cells or indirectly via
somatostatin, as discussed above.
Conclusions
In summary, the relevance of dysfunctional glucagon secre-
tion to the pathogenesis of diabetes has been widely recog-
nized and, for that reason, targeting glucagon and not only
insulin secretion abnormalities in the treatment of T2D has
gained increased interest. The well-established actions of
GLP-1 as a negative regulator of glucagon and as a positive
regulator of insulin and the availabitily of GLP-1RA and
DPP-4i provide the opportunity of targeting both main hor-
mones implicated in diabetes pathophysiology. Whether
these drugs allow a possible recovery of beta-to-alpha cell
mass is a new open avenue for researching.
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